KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya
7.2.2023 04:10:00 EET | Business Wire | Press release
The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya. Validation of this system is taking place through KEMRI with a clinical trial that began in September 2022 at the Kinango Sub-County Hospital in Kwale.
The digital system being provided by NEC, a leader in the integration of IT and network technologies, and KEMRI, one of Africa’s leading research Institutions, will effectively and seamlessly manage vaccination history and scheduling using fingerprint identification for newborn children and voice recognition for caregivers.
This technology marks the first time that biometric identification is being used at a hospital to identify newborn children at the time of vaccination, including those immediately after delivery (*1).
In terms of background, many children around the world continue to lose their lives at a very young age. In 2020 alone, approximately 5 million children died before reaching their fifth birthday. Furthermore, about half of these children under the age of five, or 2.4 million children, passed away within 28 days of birth, with many of the deaths considered preventable (*2).
Meanwhile, in some regions in the world, the use of digital technology has not advanced due to delays in the development of electricity and telecommunications infrastructure. In these regions, medical services may only be recorded by hand. In such cases, health care providers cannot easily ascertain which medical services are needed for the caregivers and children who visit their hospitals, which is one of the factors hindering efforts to ensure that children receive the vaccinations they need.
The new technology combines fingerprint identification for children and voice recognition for caregivers to confirm not only their identity, but also to reliably manage vaccination histories and schedules, thereby promoting the implementation of appropriate vaccinations for newborns and children during the first 24 months of life. Going forward, demonstration tests that network multiple hospitals will begin, aiming for full-scale introduction throughout Kenya by the end of 2023, and more international deployment in the future.
Voice and fingerprint data will be deleted after completion of the trial.
Link to press release:
https://www.nec.com/en/press/202302/global_20230207_01.html
Notes:
(*1) NEC research as of February 7, 2023
(*2) Source: Levels and trends in child mortality, Report 2021, UN-IGME
https://data.unicef.org/resources/levels-and-trends-in-child-mortality/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005304/en/
Contact information
Joseph Jasper
j-jasper(at)nec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 09:00:00 EEST | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in children and adolescents with neurological conditions, including CP. This condition is associated with muscle tightness that can severely restrict physical movement, daily functioning, and personal autonomy. Among children and youth, CP stands as a primary driver of this symptom and remains the most prevalent childhood motor disability,
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 09:00:00 EEST | Press release
The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives that can improve care for people living with haemoglobinopathies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916107487/en/ Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. Avanzanite enabled the establishment of the Network in recognition of both the considerable expertise that already exists across the Mediterranean and the persistent gaps that remain in access to specialist care, sustainable blood supplies, treatment advances and evidence-based inn
IKI Advances Promotional Forecast Accuracy by More Than 10 Points With SymphonyAI17.9.2026 08:03:00 EEST | Press release
SymphonyAI, a global leader in Vertical AI, today announced that IKI, one of Lithuania's largest grocery retailers, is implementing SymphonyAI's Promotional Evaluation and Promotional Planning solutions across its network of 250 stores, as part of its strategy to strengthen data-driven promotional planning. IKI continuously evaluates opportunities to strengthen its category management and promotional planning capabilities. As promotional programs become increasingly sophisticated, the retailer has invested in advanced analytics and AI-driven forecasting to support data-driven decision making across its business. In its initial work with SymphonyAI across select categories, IKI has seen promotional forecast accuracy improve by more than 10 percentage points, along with a reduction in stock-outs during promotional periods. "At IKI, we are constantly looking for innovative ways to strengthen our decision-making with better data and technology," said Klavs Berzins, Head of Category Managem
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family17.9.2026 05:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on system control and security across next-generation systems. "The demands on system control and security are accelerating as post-quantum mandates take hold, and customers building long-lifecycle infrastructure seek solutions that will help them design with today and tomorrow’s security needs in mind," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Mach-N2 represents a significant step forward in logic density and bandwidth while adding the most complete post-qua
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 05:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom